{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:48:50Z","timestamp":1790804930755,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gobierno Vasco \u2013 Eusko Jaurlaritza","award":["2020222004"],"award-info":[{"award-number":["2020222004"]}]},{"name":"Biocruces Bizkaia HRI","award":["BCB\/I\/LIB\/22\/008"],"award-info":[{"award-number":["BCB\/I\/LIB\/22\/008"]}]},{"DOI":"10.13039\/501100019927","name":"Universidad de Deusto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019927","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Crohn\u2019s disease (CD) is a progressive disorder leading to cumulative bowel damage. The L\u00e9mann index is a validated tool that can help in monitoring the progression of the disease and evaluating the effectiveness of different therapies. Our aim was to describe the main radiological findings in incidentally diagnosed CD and to evaluate bowel damage in this subgroup compared to patients diagnosed at later stages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with an incidental diagnosis of CD during the colorectal cancer screening program\u00a0were compared to controls with a CD cohort diagnosed after symptomatic onset and matched 1:1 by disease extent. All cross-sectional examinations were centrally read, performing a descriptive analysis of the main findings and calculation of L\u00e9mann index.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-eight patients were included: 19 with preclinical CD (median age 55 years (IQR, 54\u201362), 53% male, 74% non-smokers; 74% B1 and 26% B2) and 19 matched-controls with symptomatic CD. In those with preclinical CD, the most frequent transmural findings on MRE were contrast enhancement (79%), wall thickening (79%), followed by lymphadenopathy (68%), edema (42%), and increased vascularity (42%). Among those with strictures, controls showed a higher rate of preestenotic dilation (100% vs. 0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). Bowel damage assessment revealed no statistically significant differences in the L\u00e9mann index between preclinical CD and controls (<jats:italic>p<\/jats:italic>\u2009=\u20090.95). A statistically significant higher score in the colonic\/rectum score was observed (<jats:italic>p<\/jats:italic>\u2009=\u20090.014).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with preclinical CD demonstrate similar radiological findings and degree of bowel damage as new-onset symptomatic CD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00384-024-04660-5","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T03:44:19Z","timestamp":1718336659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn\u2019s disease: a case-control study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-4578","authenticated-orcid":false,"given":"Iago","family":"Rodr\u00edguez-Lago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aduna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9318-730X","authenticated-orcid":false,"given":"Patricia","family":"Ram\u00edrez de la Piscina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-998X","authenticated-orcid":false,"given":"Rebeca","family":"Higuera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Ma\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3068-5659","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Cabriada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-1477","authenticated-orcid":false,"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"4660_CR1","unstructured":"Collaborators GBDIBD (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5(1):17\u201330"},{"issue":"1","key":"4660_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A et al (2020) Crohn\u2019s disease. Nat Rev Dis Primers 6(1):22","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4660_CR3","first-page":"92","volume":"20","author":"M Iglesias-Rey","year":"2014","unstructured":"Iglesias-Rey M, Barreiro-de Acosta M, Caamano-Isorna F, Rodriguez IV, Ferreiro R, Lindkvist B et al (2014) Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis 20(1):92\u2013102","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"4660_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","volume":"68","author":"J Burisch","year":"2019","unstructured":"Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V et al (2019) Natural disease course of Crohn\u2019s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 68(3):423\u2013433","journal-title":"Gut"},{"issue":"13","key":"4660_CR5","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/jcm10132885","volume":"10","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Nunez Ortiz A, Diz-Lois Palomares MT, Rodriguez C, Riestra S et al (2021) Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. J Clin Med 10(13):2885","journal-title":"J Clin Med"},{"issue":"6","key":"4660_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/apt.17370","volume":"57","author":"N Jayasooriya","year":"2023","unstructured":"Jayasooriya N, Baillie S, Blackwell J, Bottle A, Petersen I, Creese H et al (2023) Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 57(6):635\u2013652","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"4660_CR7","first-page":"443","volume":"33","author":"I Rodriguez-Lago","year":"2020","unstructured":"Rodriguez-Lago I, Zabana Y, Barreiro-de Acosta M (2020) Diagnosis and natural history of preclinical and early inflammatory bowel disease. Ann Gastroenterol 33(5):443\u2013452","journal-title":"Ann Gastroenterol"},{"issue":"9","key":"4660_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.cgh.2017.11.006","volume":"16","author":"I Rodriguez-Lago","year":"2018","unstructured":"Rodriguez-Lago I, Merino O, Azagra I, Maiz A, Zapata E, Higuera R et al (2018) Characteristics and progression of preclinical inflammatory bowel disease. Clin Gastroenterol Hepatol 16(9):1459\u20131466","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"4660_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.dld.2020.05.052","volume":"52","author":"I Rodriguez-Lago","year":"2020","unstructured":"Rodriguez-Lago I, Ramirez C, Merino O, Azagra I, Maiz A, Zapata E et al (2020) Early microscopic findings in preclinical inflammatory bowel disease. Dig Liver Dis 52(12):1467\u20131472","journal-title":"Dig Liver Dis"},{"issue":"9","key":"4660_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ecco-jcc\/jjab048","volume":"15","author":"J Torres","year":"2021","unstructured":"Torres J, Halfvarson J, Rodriguez-Lago I, Hedin CRH, Jess T, Dubinsky M et al (2021) Results of the Seventh Scientific Workshop of ECCO: precision medicine in IBD-prediction and prevention of inflammatory bowel disease. J Crohns Colitis 15(9):1443\u20131454","journal-title":"J Crohns Colitis"},{"issue":"1","key":"4660_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ueg2.12352","volume":"11","author":"I Rodriguez-Lago","year":"2023","unstructured":"Rodriguez-Lago I, Aguirre U, de la Ramirez P, Munagorri A, Zapata E, Higuera R et al (2023) Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease. United Eur Gastroenterol J 11(1):9\u201318","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"4660_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V et al (2019) ECCO-ESGAR Guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144\u2013164","journal-title":"J Crohns Colitis"},{"issue":"4","key":"4660_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/ibd\/izac116","volume":"29","author":"A Rispo","year":"2023","unstructured":"Rispo A, de Sire R, Mainenti PP, Imperatore N, Testa A, Maurea S et al (2023) David against Goliath: direct comparison of handheld bowel sonography and magnetic resonance enterography for diagnosis of Crohn\u2019s disease. Inflamm Bowel Dis 29(4):563\u2013569","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"4660_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2014.09.015","volume":"148","author":"B Pariente","year":"2015","unstructured":"Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D\u2019Haens G et al (2015) Development of the Lemann index to assess digestive tract damage in patients with Crohn\u2019s disease. Gastroenterology 148(1):52\u201363","journal-title":"Gastroenterology"},{"issue":"3","key":"4660_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.gastro.2021.05.049","volume":"161","author":"B Pariente","year":"2021","unstructured":"Pariente B, Torres J, Burisch J, Arebi N, Barberio B, Duricova D et al (2021) Validation and update of the Lemann index to measure cumulative structural bowel damage in Crohn\u2019s disease. Gastroenterology 161(3):853\u2013864","journal-title":"Gastroenterology"},{"issue":"9","key":"4660_CR16","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.cgh.2015.02.041","volume":"13","author":"C Gilletta","year":"2015","unstructured":"Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L et al (2015) Changes in the Lemann index values during the first years of Crohn\u2019s disease. Clin Gastroenterol Hepatol 13(9):1633\u20131640","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"4660_CR17","first-page":"274","volume":"11","author":"G Fiorino","year":"2017","unstructured":"Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A et al (2017) Prevalence of bowel damage assessed by cross-sectional Imaging in early Crohn\u2019s disease and its impact on disease outcome. J Crohns Colitis 11(3):274\u2013280","journal-title":"J Crohns Colitis"},{"issue":"12","key":"4660_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.crohns.2013.09.016","volume":"7","author":"V Annese","year":"2013","unstructured":"Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J et al (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn\u2019s Colitis 7(12):982\u20131018","journal-title":"J Crohn\u2019s Colitis"},{"issue":"10","key":"4660_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.crohns.2013.06.001","volume":"7","author":"F Magro","year":"2013","unstructured":"Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ et al (2013) European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7(10):827\u2013851","journal-title":"J Crohns Colitis"},{"issue":"6","key":"4660_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749\u2013753","journal-title":"Gut"},{"issue":"2","key":"4660_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/DCR.0000000000000930","volume":"61","author":"W Liu","year":"2018","unstructured":"Liu W, Zhou W, Xiang J, Cao Q, Zhu J, Qi W et al (2018) Lemann Index at diagnosis predicts the risk of early surgery in Crohn\u2019s disease. Dis Colon Rectum 61(2):207\u2013213","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"4660_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12876-020-01575-7","volume":"20","author":"M Zhu","year":"2020","unstructured":"Zhu M, Feng Q, Xu X, Qiao Y, Cui Z, Yan Y et al (2020) Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn\u2019s disease, based on the Lemann index. BMC Gastroenterol 20(1):421","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4660_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ueg2.12356","volume":"11","author":"SR Fernandes","year":"2023","unstructured":"Fernandes SR, Serrazina J, Botto IA, Leal T, Guimaraes A, Garcia JL et al (2023) Transmural remission improves clinical outcomes up to 5 years in Crohn\u2019s disease. United Eur Gastroenterol J 11(1):51\u201359","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"4660_CR24","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/j.cgh.2021.03.011","volume":"20","author":"T Okamoto","year":"2022","unstructured":"Okamoto T, Fukuda K (2022) Long-term outcomes in asymptomatic ulcerative colitis diagnosed during screening colonoscopy. Clin Gastroenterol Hepatol 20(2):e319\u2013e25","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"4660_CR25","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.13641","volume":"43","author":"RS Choung","year":"2016","unstructured":"Choung RS, Princen F, Stockfisch TP, Torres J, Maue AC, Porter CK et al (2016) Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther 43(12):1300\u20131310","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4660_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1053\/j.gastro.2022.05.029","volume":"163","author":"A Mortha","year":"2022","unstructured":"Mortha A, Remark R, Del Valle DM, Chuang LS, Chai Z, Alves I et al (2022) Neutralizing anti-granulocyte macrophage-colony stimulating factor autoantibodies recognize post-translational glycosylations on granulocyte macrophage-colony stimulating factor years before diagnosis and predict complicated Crohn\u2019s disease. Gastroenterology 163(3):659\u2013670","journal-title":"Gastroenterology"},{"issue":"4","key":"4660_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos AE, Dunn A, Fischer J, Ungaro RC, Turpin W, Lee SH et al (2023) Anti-integrin alphavbeta6 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164(4):619\u2013629","journal-title":"Gastroenterology"},{"issue":"1","key":"4660_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","volume":"159","author":"J Torres","year":"2020","unstructured":"Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS et al (2020) Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 159(1):96\u2013104","journal-title":"Gastroenterology"},{"issue":"11","key":"4660_CR29","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1016\/j.cgh.2023.01.033","volume":"21","author":"RS Choung","year":"2023","unstructured":"Choung RS, Petralia F, Torres J, Ungaro RC, Porter C, Sato T et al (2023) Preclinical serological signatures are associated with complicated Crohn\u2019s disease phenotype at diagnosis. Clin Gastroenterol Hepatol 21(11):2928\u201337","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"4660_CR30","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1136\/gutjnl-2022-328421","volume":"72","author":"H Leibovitzh","year":"2023","unstructured":"Leibovitzh H, Lee SH, Raygoza Garay JA, Espin-Garcia O, Xue M, Neustaeter A et al (2023) Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn\u2019s disease highlight earliest events of pathogenesis. Gut 72(8):1462\u20131471","journal-title":"Gut"},{"issue":"5","key":"4660_CR31","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1053\/j.gastro.2020.12.004","volume":"160","author":"HJ Galipeau","year":"2021","unstructured":"Galipeau HJ, Caminero A, Turpin W, Bermudez-Brito M, Santiago A, Libertucci J et al (2021) Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology 160(5):1532\u20131545","journal-title":"Gastroenterology"},{"issue":"6","key":"4660_CR32","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1053\/j.gastro.2020.08.005","volume":"159","author":"W Turpin","year":"2020","unstructured":"Turpin W, Lee SH, Raygoza Garay JA, Madsen KL, Meddings JB, Bedrani L et al (2020) Increased intestinal permeability is associated with later development of Crohn\u2019s disease. Gastroenterology 159(6):2092\u20132100","journal-title":"Gastroenterology"},{"key":"4660_CR33","doi-asserted-by":"crossref","unstructured":"Park S, Lee HJ, Han KD, Soh H, Moon JM, Hong SW et al (2021) Proteinuria is associated with the development of Crohn\u2019s disease: a nationwide population-based study. J Clin Med 10(4)","DOI":"10.3390\/jcm10040799"},{"issue":"9","key":"4660_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/ibd\/izz265","volume":"26","author":"K Vadstrup","year":"2020","unstructured":"Vadstrup K, Alulis S, Borsi A, Gustafsson N, Nielsen A, Wennerstrom ECM et al (2020) Cost burden of Crohn\u2019s disease and ulcerative colitis in the 10-year period before diagnosis-a Danish register-based study from 2003\u20132015. Inflamm Bowel Dis 26(9):1377\u20131382","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"4660_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.dld.2021.04.002","volume":"53","author":"I Rodriguez-Lago","year":"2021","unstructured":"Rodriguez-Lago I, Agirre U, Intxaurza N, Cantero D, Cabriada JL, Barreiro-de Acosta M (2021) Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. Dig Liver Dis 53(7):927\u2013930","journal-title":"Dig Liver Dis"},{"issue":"1","key":"4660_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ecco-jcc\/jjac111","volume":"17","author":"J Torres","year":"2023","unstructured":"Torres J, Gomes C, Jensen CB, Agrawal M, Ribeiro-Mourao F, Jess T et al (2023) Risk factors for developing inflammatory bowel disease within and across families with a family history of IBD. J Crohns Colitis 17(1):30\u201336","journal-title":"J Crohns Colitis"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04660-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04660-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04660-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:21:38Z","timestamp":1736328098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04660-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4660"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04660-5","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"27 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Ethics Committee, and informed consent was provided before any study procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"IR-L has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Celltrion, Chiesi, Danone, Ferring, Faes Farma, Janssen, Galapagos, MSD, Pfizer, Roche, Takeda, and Tillotts Pharma. Financial support for research: Tillotts Pharma. MB-A has received financial support for traveling and educational activities from or has served as an advisory board member for Pfizer, MSD, Takeda, AbbVie, Kern, Janssen, Fresenius Kabi, Galapagos, Lilly, BMS, Faes Farma, Chiesi, and Adacyte. The remaining authors report no conflict of interest related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}